Zydus Lifesciences, a pharmaceutical company based in Ahmedabad, India, is reportedly nearing an acquisition of a US-based oncology drug manufacturer, with the deal valued between $100 million and $150 million. This strategic acquisition is expected to bolster Zydus's portfolio in the oncology sector, particularly in the distribution of anti-cancer medications in the US market, which is experiencing significant growth. The target company is noted for its pipeline of biologic drugs, which aligns with Zydus's goal of expanding its innovative drug offerings. For several months, Zydus has been actively seeking to enhance its drug pipeline and has previously engaged in discussions with other firms, including Ardelyx, although those negotiations did not lead to a deal. The acquisition is anticipated to be finalized soon, further positioning Zydus as a key player in the oncology market.